An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose dexamethasone by itself.

Key facts

Study ID

NCT02654132

Run by

Bristol-Myers Squibb

People needed

117

Starts

2016-03-18

Expected to finish

2021-10-21

Last updated by the study team

2022-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination
• Documented refractory or relapsed and refractory multiple myeloma
• Refractory to proteosome inhibitor and lenalidomide, and to last treatment
• Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment
• Measurable disease at screening
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

You may not qualify if…

• Active plasma cell leukemia
• Prior treatment with pomalidomide
• Unable to tolerate thromboembolic prophylaxis while on the study
• Prior autologous stem cell transplant within 12 weeks
• Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

Where it is running

• Rush University Medical Center — Chicago, Illinois, United States
• Investigative Clinical Research Of Indiana, Llc — Indianapolis, Indiana, United States
• Beth Israel Comprehensive Cancer Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute. — Boston, Massachusetts, United States
• Rochester General Hospital — Rochester, New York, United States
• Carolinas Healthcare System — Charlotte, North Carolina, United States
• Va Pittsburgh Healthcare System — Pittsburgh, Pennsylvania, United States
• St Francis Hospital — Greenville, South Carolina, United States
• Tennessee Cancer Specialists — Knoxville, Tennessee, United States
• Northern Utah Associates — Ogden, Utah, United States
• University Of Washington — Seattle, Washington, United States
• Local Institution — South Brisbane, Queensland, Australia
• Local Institution — London, Ontario, Canada
• CISSS de l'Outaouais — Gatineau, Quebec, Canada
• Local Institution - 0048 — Montreal, Quebec, Canada
• Local Institution - 0022 — Nantes, France
• Local Institution - 0021 — Paris, France
• Local Institution - 0020 — Pessac, France
• Local Institution - 0019 — Poitiers, France
• Local Institution — Saint-Pierre, France
• Universitaetsklinikum Carl Gustav Carus — Dresden, Germany
• Universitaetsklinikum Freiburg — Freiburg im Breisgau, Germany
• St. Barbara-Klinik — Hamm, Germany
• Local Institution - 0041 — Heidelberg, Germany
• Winship Cancer Institute — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.